SCHEMBL5488829

SCHEMBL5488829

Cc1ncccc1-c1ccc2nc(N[C@H]3CC[C@H](O)CC3)ncc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 4/20 0.60
JUN P05412 2/20 0.60
ADORA1 P30542 4/20 0.52
ADORA2A P29274 3/20 0.52
ADORA2B P29275 1/20 0.52
RIPK2 O43353 1/20 0.52
ABL1 P00519 2/20 0.48
LCK P06239 2/20 0.47
KDR P35968 2/20 0.47
MAPK14 Q16539 2/20 0.47
JAK3 P52333 1/20 0.47
MAPK8 P45983 2/20 0.45
MAPK9 P45984 1/20 0.45
AXL P30530 4/20 0.44
TYRO3 Q06418 4/20 0.44
MERTK Q12866 4/20 0.44
FLT3 P36888 1/20 0.44
GAS6 Q14393 1/20 0.44
RET P07949 1/20 0.43
CDC7 O00311 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5488834 1.00 MAPK10 (0.60) MAPK10JUNADORA1ADORA2AADORA2B
SCHEMBL5492979 0.87 RIPK2 (0.64) MAPK10JUNADORA1ADORA2AADORA2B
SCHEMBL14569053 0.87 RIPK2 (0.64) MAPK10JUNADORA1ADORA2AADORA2B
SCHEMBL14569015 0.85 MAPK10 (0.52) MAPK10JUNADORA1ADORA2AADORA2B
SCHEMBL5492986 0.85 MAPK10 (0.52) MAPK10JUNADORA1ADORA2AADORA2B
SCHEMBL5498511 0.83 RIPK2 (0.52) MAPK10JUNADORA1ADORA2AADORA2B
SCHEMBL5497234 0.83 RIPK2 (0.52) MAPK10JUNADORA1ADORA2AADORA2B
SCHEMBL5495735 0.83 ADORA1 (0.56) MAPK10JUNADORA1ADORA2AADORA2B
SCHEMBL14569054 0.83 ADORA1 (0.56) MAPK10JUNADORA1ADORA2AADORA2B
SCHEMBL5496767 0.82 LCK (0.54) MAPK10JUNADORA1ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 MAPK10 347/4885JUN 1821/4885ADORA1 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.